]>
IRCT2016100930224N1 IRCT 2016-11-27 Vice chancellor for research, Shiraz University of Medical Sciences Comparison of intravitreal anti-VEGF drug and steroid in the treatment of uveitic macular edema Comparison of intravitreal injection of bevacizumab and triamcinolone acetonide in the treatment of uveitic macular edema 2016-11-20 anticipated 60 Complete https://irct.ir/trial/24085 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2 Macular edema in uveitic eyes. Intervention 1: The eyes will randomly divided into two groups; the 1st group will receive 0.05 ml (1.25 mg) intravitreal Bevacizvmab (IVB). Intervention 2: The eyes will randomly divided into two groups; the 2nd group will recive 0.05ml (2mg) Triamcinolone acetonide intravitreally.
public Dr. Mansour Rahimi
Shiraz University of Medical Sciences central building, Zand BLVD, Shiraz, Iran
Shiraz Iran (Islamic Republic of) 7134997446 +98 71 3481 4336 mrahimi@ucla.edu Shiraz University of Medical Sciences scientific Dr. Mansour Rahimi
Shiraz University of Medical Sciences central building, Zand BLVD, Shiraz, Iran
Shiraz Iran (Islamic Republic of) 7134997446 +98 71 3481 4336 mrahimi@ucla.edu Shiraz University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: patients with inactive uveitis, according to sun group classification, who had visual loss due to macular edema (diagnosed by optical coherence tomography (OCT)) and not responding to topical medication such as steroid. Exclusion criteria included any other ophthalmic disease that causes macular edema (e.g. diabetes, venous occlusive diseases); any intraocular surgery within 3 months of injection; media opacity that hinders assessment of macula by OCT, prior vitrectomy; Glaucoma; ocular hypertension and monocularity. 9 years 47 years Both H30.9 Chorioretinal inflammation, unspecified Treatment - Drugs Treatment - Drugs The eyes will randomly divided into two groups; the 1st group will receive 0.05 ml (1.25 mg) intravitreal Bevacizvmab (IVB). The eyes will randomly divided into two groups; the 2nd group will recive 0.05ml (2mg) Triamcinolone acetonide intravitreally. Macular thickness. Timepoint: 3, 6 and 12 months after injection of drug. Method of measurement: Optical Coherence Tomography. Visual acuity. Timepoint: 3, 6 and 12 months after injection. Method of measurement: Snellen chart. Vice chancellor for research, Shiraz University of Medical Sciences Approved 2013-10-26 Shiraz University of Medical Sciences Shiraz University of Medical Sciences central building, Zand BLVD, Shiraz, Iran Shiraz Iran (Islamic Republic of)